Here are four things to know:
1. The report authors note the Asia-Pacific region is likely to overtake Europe due to the growing prevalence of HAIs in this area.
2. From 2016 to 2024, the antibacterial segment is likely to grow due to higher demand for antibiotics around the globe.
3. Urinary tract infections are the most common HAI, with this type of infection having the highest compound annual growth rate through 2024.
4. Market vendors include:
● Chicago-based Abbott
● AstraZeneca in London, United Kingdom
● Bayer in Leverkusen, Germany
● Pfizer in New York City
● Lexington, Mass.-based Cubist Pharmaceuticals
● GlaxoSmithKline in Brentford, United Kingdom
● Cepheid in Sunnyvale, Calif.
● Johnson & Johnson in New Brunswick, N.J.
● Merck & Co. in Kenilworth, N.J.
● Cipla in Mumbai, India
● Astellas Pharma in Tokyo, Japan
● Aridis Pharmaceuticals in San Jose, Calif.
● Daiichi Sankyo in Tokyo
● Indianapolis-based Eli Lilly and Co.
● Bristol-Myers Squibb Co. in New York City
● F. Hoffmann-La Roche in Basel, Switzerland
More articles on quality & infection control:
10 most popular quality and infection control stories of 2016
5 key takeaways on the global infection control market
The 5 most common types of sentinel event outcomes in Q2 2016
